These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16505405)

  • 21. Radiation exposure during cardiac CT: effective doses at multi-detector row CT and electron-beam CT.
    Hunold P; Vogt FM; Schmermund A; Debatin JF; Kerkhoff G; Budde T; Erbel R; Ewen K; Barkhausen J
    Radiology; 2003 Jan; 226(1):145-52. PubMed ID: 12511683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seizure after gadolinium administration.
    Hailemeskal B; Ilogu E; Khuc K; Curry C; Kelvas M
    Radiol Technol; 1999; 70(4):387. PubMed ID: 10101755
    [No Abstract]   [Full Text] [Related]  

  • 23. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?
    Thomsen HS; Marckmann P; Logager VB
    Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter to the editor regarding 'Acute phase reaction to gadolinium-DTPA in dialysis patients'.
    Swaminathan S; Shah SV
    Nephrol Dial Transplant; 2009 Jul; 24(7):2295-6; author reply 2296. PubMed ID: 19395733
    [No Abstract]   [Full Text] [Related]  

  • 25. Renal failure and gadolinium. The number of documented cases is rising.
    Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
    [No Abstract]   [Full Text] [Related]  

  • 26. Gadodiamide administration causes spurious hypocalcemia.
    Prince MR; Erel HE; Lent RW; Blumenfeld J; Kent KC; Bush HL; Wang Y
    Radiology; 2003 Jun; 227(3):639-46. PubMed ID: 12773671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 28. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [CT angiography (CTA)].
    Fleischmann D
    Wien Med Wochenschr Suppl; 2002; (113):53-8. PubMed ID: 12621843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent.
    Fujisaki K; Ono-Fujisaki A; Kura-Nakamura N; Komune N; Hirakawa N; Tsuruya K; Komune S; Iida M
    Clin Nephrol; 2011 Mar; 75(3):251-4. PubMed ID: 21329636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac arrest caused by IV gadopentetate dimeglumine.
    Unal O; Arslan H
    AJR Am J Roentgenol; 1999 Apr; 172(4):1141. PubMed ID: 10587169
    [No Abstract]   [Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of gadolinium chelates as an alternative radiographic contrast agent for use with flat panel detector angiography.
    Hui FK; Tong FC; Dion JE
    J Neurointerv Surg; 2011 Mar; 3(1):95-7. PubMed ID: 21990800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effects of gadolinium administration in hemodialysis patients: a role for chromium supplementation?
    Reinhardt C; Vaccaro DE; Groman EV
    Am J Kidney Dis; 2008 Nov; 52(5):1021; author reply 1021-2. PubMed ID: 18971016
    [No Abstract]   [Full Text] [Related]  

  • 35. Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data.
    Nyman U; Elmståhl B; Leander P
    Radiology; 2007 Aug; 244(2):622-3. PubMed ID: 17641384
    [No Abstract]   [Full Text] [Related]  

  • 36. Nephrogenic systemic fibrosis and gadolinium: a perfect storm.
    Colletti PM
    AJR Am J Roentgenol; 2008 Oct; 191(4):1150-3. PubMed ID: 18806157
    [No Abstract]   [Full Text] [Related]  

  • 37. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gadolinium-based contrast agents and nephrotoxicity.
    Morcos SK
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):812; author reply 813. PubMed ID: 17039541
    [No Abstract]   [Full Text] [Related]  

  • 39. Coronary artery stent patency assessed with in-stent contrast enhancement measured at multi-detector row CT angiography: initial experience.
    Hong C; Chrysant GS; Woodard PK; Bae KT
    Radiology; 2004 Oct; 233(1):286-91. PubMed ID: 15304660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gadolinium-based contrast media may be nephrotoxic even at approved doses.
    Thomsen HS
    Eur Radiol; 2004 Sep; 14(9):1654-6. PubMed ID: 15221265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.